Clarence Ahlem
Chief Operating Officer at NeurMedix, Inc.
Net worth: 18 165 $ as of 30/04/2024
Profile
Clarence Ahlem currently works at NeurMedix, Inc., as Chief Operating Officer.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BIOVIE INC. CLASS A
0.07% | 16/02/2023 | 37,148 ( 0.07% ) | 18 165 $ | 30/04/2024 |
Clarence Ahlem active positions
| Companies | Position | Start |
|---|---|---|
NeurMedix, Inc.
 NeurMedix, Inc. Pharmaceuticals: MajorHealth Technology NeurMedix, Inc. is a clinical-stage biopharmaceutical company that develops products for the treatment of neurological and neuro-degenerative disorders and certain cancers. NeurMedix is based in San Diego, CA, and was founded by Terren S. Peizer, who has been the CEO since incorporation. The private company's product candidates have completed several pre-clinical and clinical studies, indicating its broad anti-inflammatory effect without evidence of immunosuppression. NeurMedix has invested over $85 million in developing NE3107, and its focus is on diseases with significant unmet medical needs and commercial potential. The company plans to enter clinical trials for the treatment of Parkinson's disease and several oncological indications later this year. | Chief Operating Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
NeurMedix, Inc.
NeurMedix, Inc. Pharmaceuticals: MajorHealth Technology NeurMedix, Inc. is a clinical-stage biopharmaceutical company that develops products for the treatment of neurological and neuro-degenerative disorders and certain cancers. NeurMedix is based in San Diego, CA, and was founded by Terren S. Peizer, who has been the CEO since incorporation. The private company's product candidates have completed several pre-clinical and clinical studies, indicating its broad anti-inflammatory effect without evidence of immunosuppression. NeurMedix has invested over $85 million in developing NE3107, and its focus is on diseases with significant unmet medical needs and commercial potential. The company plans to enter clinical trials for the treatment of Parkinson's disease and several oncological indications later this year. | Health Technology |
- Stock Market
- Insiders
- Clarence Ahlem
